Canadian corporation the Centre for Probe Development and Commercialization (CPDC) has closed its phase III trial of F-18 PSMA-1007, a PET radiotracer designed for prostate cancer imaging.
The closure of the trial is a significant milestone on the path to submission for Canadian regulatory approval, with submission of the trial results to Health Canada expected later this year, the CPDC said.
The CPDC has licensed F-18 PSMA-1007 from ABX Advanced Biochemical Compounds of Radeberg, Germany, and holds the exclusive license to develop, manufacture, and distribute the imaging agent in Canada.
